{"id":"taxane-plus-metronomic-capecitabine","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Hand-foot syndrome"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Taxanes, such as paclitaxel, work by stabilizing microtubules, thereby inhibiting cell division. Metronomic capecitabine, on the other hand, is a prodrug that is converted into 5-fluorouracil, which then inhibits thymidylate synthase, leading to DNA damage and cell death.","oneSentence":"Taxane inhibits microtubule dynamics, while metronomic capecitabine targets thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:32.559Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06217185","phase":"PHASE4","title":"The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-02","conditions":"HER2-positive Breast Cancer, Advanced Breast Cancer","enrollment":100},{"nctId":"NCT02954055","phase":"PHASE2","title":"MEtronomic TrEatment Option in Advanced bReast cAncer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-09-13","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT05172518","phase":"PHASE3","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-03-01","conditions":"Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer","enrollment":512},{"nctId":"NCT01917279","phase":"PHASE3","title":"Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC","status":"UNKNOWN","sponsor":"Binghe Xu","startDate":"2013-10","conditions":"Breast Neoplasms, Neoplasms by Site, Neoplasm Metastasis","enrollment":280},{"nctId":"NCT01131195","phase":"PHASE3","title":"Metronomic Therapy in Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-07-19","conditions":"Breast Cancer","enrollment":139},{"nctId":"NCT02007148","phase":"PHASE2","title":"MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"International Group of Endovascular Oncology","startDate":"2013-11","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":51},{"nctId":"NCT01887288","phase":"PHASE2","title":"Capecitabine With Digoxin for Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Western Regional Medical Center","startDate":"2013-04","conditions":"Metastatic Breast Cancer","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Taxane plus Metronomic Capecitabine","genericName":"Taxane plus Metronomic Capecitabine","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taxane inhibits microtubule dynamics, while metronomic capecitabine targets thymidylate synthase. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}